• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

FK-037、头孢吡肟、头孢曲松、头孢他啶和头孢呋辛体外活性的多中心比较。

Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime.

作者信息

Washington J A, Jones R N, Gerlach E H, Murray P R, Allen S D, Knapp C C

机构信息

Cleveland Clinic Foundation, Ohio 44195.

出版信息

Antimicrob Agents Chemother. 1993 Aug;37(8):1696-700. doi: 10.1128/AAC.37.8.1696.

DOI:10.1128/AAC.37.8.1696
PMID:8215286
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC188045/
Abstract

In a multicenter study, the MICs of FK-037 for 90% of the strains tested (MIC90s) were < or = 1 microgram/ml for members of the family Enterobacteriaceae other than Citrobacter freundii, Enterobacter spp., and Serratia marcescens. Activity against Pseudomonas aeruginosa was variable, with a MIC50 and a MIC90 of 4 and 32 micrograms/ml, respectively. Relative to cefepime, however, FK-037 was less active against ceftazidime-resistant isolates of Enterobacter cloacae. The MIC90 of FK-037 for methicillin-resistant staphylococci was > 16 micrograms/ml.

摘要

在一项多中心研究中，对于弗氏柠檬酸杆菌、肠杆菌属和粘质沙雷氏菌以外的肠杆菌科成员，FK-037对90%受试菌株的最低抑菌浓度（MIC90）≤1微克/毫升。其对铜绿假单胞菌的活性各不相同，MIC50和MIC90分别为4微克/毫升和32微克/毫升。然而，相对于头孢吡肟，FK-037对阴沟肠杆菌头孢他啶耐药菌株的活性较低。FK-037对耐甲氧西林葡萄球菌的MIC90>16微克/毫升。

相似文献

1
Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime.FK-037、头孢吡肟、头孢曲松、头孢他啶和头孢呋辛体外活性的多中心比较。
Antimicrob Agents Chemother. 1993 Aug;37(8):1696-700. doi: 10.1128/AAC.37.8.1696.
2
Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.新型胃肠外头孢菌素FK-037抗菌活性的多中心比较研究
Eur J Clin Microbiol Infect Dis. 1995 Mar;14(3):244-52. doi: 10.1007/BF02310366.
3
Antimicrobial activity of FK-037, a new broad-spectrum cephalosporin. International in vitro comparison with cefepime and ceftazidime.新型广谱头孢菌素FK-037的抗菌活性。与头孢吡肟和头孢他啶的国际体外比较。
Diagn Microbiol Infect Dis. 1994 Mar;18(3):167-73. doi: 10.1016/0732-8893(94)90087-6.
4
In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.新型注射用头孢菌素FK037的体外和体内抗菌活性
Chemotherapy. 1994 May-Jun;40(3):167-82. doi: 10.1159/000239189.
5
In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin.注射用头孢菌素FK-037的体外活性及β-内酰胺酶稳定性
Antimicrob Agents Chemother. 1993 Mar;37(3):566-73. doi: 10.1128/AAC.37.3.566.
6
In vitro comparison of GR69153, a novel catechol-substituted cephalosporin, with ceftazidime and ceftriaxone against 5,203 recent clinical isolates.新型儿茶酚取代头孢菌素GR69153与头孢他啶和头孢曲松针对5203株近期临床分离株的体外比较
Antimicrob Agents Chemother. 1991 Jul;35(7):1508-11. doi: 10.1128/AAC.35.7.1508.
7
In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.抗耐甲氧西林金黄色葡萄球菌头孢菌素头孢比普对近期源自欧洲的革兰氏阳性和革兰氏阴性分离株的体外活性谱
J Antimicrob Chemother. 2008 Mar;61(3):595-602. doi: 10.1093/jac/dkm492. Epub 2008 Jan 23.
8
Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).针对儿科患者分离出的细菌进行的肠外广谱头孢菌素比较：哨兵抗菌监测计划（1998 - 2004年）报告
Diagn Microbiol Infect Dis. 2007 Jan;57(1):109-16. doi: 10.1016/j.diagmicrobio.2006.06.011. Epub 2006 Aug 23.
9
Activity of cefepime compared with other antibiotics against gram-positive bacteria and cefuroxime-resistant gram-negative bacteria.头孢吡肟与其他抗生素对革兰氏阳性菌及耐头孢呋辛革兰氏阴性菌的活性比较。
Zhonghua Yi Xue Za Zhi (Taipei). 1998 Jul;61(7):408-13.
10
In-vitro activities of cefepime against Enterobacter cloacae, Serratia marcescens, Pseudomonas aeruginosa and other aerobic gram-negative bacilli.头孢吡肟对阴沟肠杆菌、粘质沙雷氏菌、铜绿假单胞菌及其他需氧革兰氏阴性杆菌的体外活性。
J Antimicrob Chemother. 1993 Nov;32 Suppl B:21-9. doi: 10.1093/jac/32.suppl_b.21.

引用本文的文献

1
Importance of beta-lactam pharmacokinetics and pharmacodynamics on the recovery of microbial diversity in the airway of persons with cystic fibrosis.β-内酰胺类药物的药代动力学和药效学对囊性纤维化患者气道微生物多样性恢复的重要性。
J Investig Med. 2021 Oct;69(7):1350-1359. doi: 10.1136/jim-2021-001824. Epub 2021 May 21.
2
Post-Dialysis Parenteral Antimicrobial Therapy in Patients Receiving Intermittent High-Flux Hemodialysis.接受间歇性高通量血液透析患者的透析后肠外抗菌治疗。
Drugs. 2021 Apr;81(5):555-574. doi: 10.1007/s40265-021-01469-2. Epub 2021 Feb 16.
3
Relationship of Pulmonary Outcomes, Microbiology, and Serum Antibiotic Concentrations in Cystic Fibrosis Patients.囊性纤维化患者肺部结局、微生物学与血清抗生素浓度的关系
J Pediatr Pharmacol Ther. 2018 Sep-Oct;23(5):379-389. doi: 10.5863/1551-6776-23.5.379.
4
Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study.维持性血液透析患者每周三次透析后头孢吡肟治疗：一项回顾性研究。
BMC Pharmacol Toxicol. 2016 Feb 4;17:4. doi: 10.1186/s40360-016-0048-y.
5
Decision analysis modelling of costs and outcomes following cefepime monotherapy in Canada.加拿大头孢吡肟单药治疗后成本与结局的决策分析模型
Can J Infect Dis. 1997 Jan;8(1):19-27. doi: 10.1155/1997/106462.
6
Ceftriaxone/Amikacin vs Ceftazidime/Amikacin as Empirical Therapy for Fever in Patients with Haematological Malignancy and Severe Granulocytopenia: Clinical and Economic Outcomes.头孢曲松/阿米卡星与头孢他啶/阿米卡星治疗血液恶性肿瘤伴严重粒细胞减少发热患者的经验性治疗：临床和经济结局。
Clin Drug Investig. 1998;15(5):425-33. doi: 10.2165/00044011-199815050-00007.
7
Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia. The Cefepime Study Group.头孢吡肟与头孢曲松用于社区获得性肺炎住院患者的经验性治疗。头孢吡肟研究组。
Antimicrob Agents Chemother. 1998 Apr;42(4):729-33. doi: 10.1128/AAC.42.4.729.
8
Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.头孢呋辛酯。对其抗菌活性、药代动力学特性及治疗效果的综述。
Drugs. 1996 Jul;52(1):125-58. doi: 10.2165/00003495-199652010-00009.
9
Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis.头孢呋辛酯短程疗法（5天）治疗急性支气管炎继发细菌感染的疗效
Antimicrob Agents Chemother. 1995 Nov;39(11):2528-34. doi: 10.1128/AAC.39.11.2528.
10
Activity of the fourth generation cephalosporin FK-037 against methicillin-resistant Staphylococcus aureus under conditions maximizing PBP2' production.在使青霉素结合蛋白2′（PBP2'）产量最大化的条件下，第四代头孢菌素FK-037对耐甲氧西林金黄色葡萄球菌的活性
Eur J Clin Microbiol Infect Dis. 1994 Dec;13(12):1053-5. doi: 10.1007/BF02111826.

本文引用的文献

1
In vitro activity of FK037, a new parenteral cephalosporin, against anaerobic bacteria.新型胃肠外头孢菌素FK037对厌氧菌的体外活性
Antimicrob Agents Chemother. 1993 May;37(5):957-61. doi: 10.1128/AAC.37.5.957.
2
In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin.注射用头孢菌素FK-037的体外活性及β-内酰胺酶稳定性
Antimicrob Agents Chemother. 1993 Mar;37(3):566-73. doi: 10.1128/AAC.37.3.566.
3
In vitro and in vivo antibacterial activities of FK037, a novel parenteral broad-spectrum cephalosporin.新型注射用广谱头孢菌素FK037的体外和体内抗菌活性
Antimicrob Agents Chemother. 1993 Feb;37(2):301-7. doi: 10.1128/AAC.37.2.301.
4
Activity of cefepime (BMY-28142) and cefpirome (HR 810) against gram-negative bacilli resistant to cefotaxime or ceftazidime.头孢吡肟（BMY - 28142）和头孢匹罗（HR 810）对耐头孢噻肟或头孢他啶的革兰氏阴性杆菌的抗菌活性。
J Antimicrob Chemother. 1989 Jan;23(1):163-5. doi: 10.1093/jac/23.1.163.
5
Activity of cefepime, ceftazidime, and ceftizoxime against mutants of Enterobacteriaceae and Pseudomonas aeruginosa derepressed for class I beta-lactamase.头孢吡肟、头孢他啶和头孢唑肟对I类β-内酰胺酶去阻遏的肠杆菌科细菌和铜绿假单胞菌突变体的活性。
J Antimicrob Chemother. 1989 Dec;24(6):1011-2. doi: 10.1093/jac/24.6.1011.
6
Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.头孢吡肟对头孢他啶和头孢噻肟耐药革兰阴性菌的活性及其与β-内酰胺酶水平的关系。
Antimicrob Agents Chemother. 1989 Apr;33(4):498-502. doi: 10.1128/AAC.33.4.498.